Belimumab Injection Shortage

• • GSK did not provide a reason for the shortage.

• • Benlysta subcutaneous injection, GSK, 200 mg/mL, 1 mL auto-injector, 1 count, NDC 49401-0088-35
  • Benlysta subcutaneous injection, GSK, 200 mg/mL, 1 mL syringe, 1 count, NDC 49401-0088-47
  • Benlysta injection, GSK, 120 mg, vial, 1 count, NDC 49401-0101-01
  • Benlysta injection, GSK, 400 mg, vial, 1 count, NDC 49401-0102-01

Estimated Resupply Dates

• • GSK has Benlysta 120 mg and 400 mg vials available. The 200 mg/mL 1 mL auto-injectors and syringes are available.

Implications for Patient Care

• • Transition pediatric patients to alternative agents.
  • Start patients on subcutaneous therapy when possible.
  • Systemic lupus erythematosus (SLE) - Per package labeling, to transition to subcutaneous dosing from intravenous dosing, administer first subcutaneous dose 1 to 4 weeks after the last IV dose (200 mg once weekly).
  • Active Lupus Nephritis - Per package labeling, to transition to subcutaneous dosing from intravenous dosing, you may transition after 2 x IV doses. Administer first subcutaneous dose 1 to 2 weeks after the last IV dose (200 mg once weekly)